# GeneCradle

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genecradle

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.bj-genecradle.com
- Total disclosed funding: $47M
- Latest round: Series A (Feb 8, 2022)
- Investors on record: 8

## About

Based in Beijing, China,  and established in 2018, GeneCradle is a biotechnology company that engages in the development of gene therapy drugs. Dr Xiaobing Wu, the founder, chairman and CEO of the company, worked at the China CDC Viral Disease Institute. It has partnerships with Beijing Children's Hospital, Peking University Medical School and Guangzhou Women's and Children's Medical Center. On April 6, 2023, it received clinical approval from the State Drug Administration of China for its IND application for "GC101 adeno-associated virus injection", an AAV (adeno-associated virus) gene therapy for the treatment of spinal muscular atrophy. It has production bases in Beijing. In August 2023, GeneCradle raised pre-series B+ funding from new investor CASH Capital. 

The company's main products include gene therapy drugs for spinal muscular atrophy (SMA), gene therapy drugs for hypertriglyceridemia, gene therapy drugs for Pompe disease and gene therapy drugs for familial LCAT (Lecithin-Cholesterol Acyltransferase) deficiency. The company's products are used in genetic diseases, infectious diseases, neurological diseases, blood diseases, metabolic diseases and ophthalmic diseases.

## Funding rounds

- Series A, Feb 8, 2022, $31M — Oriental Fortune Capital, E-Town International Industrial Investment, Shenzhen Capital Real Estate Fund, Huajin Lingchuang Fund Management, E-town Sun Fund, Zhuhai Hengqin Kangju Private Equity Fund Management Co., Ltd.
- Angel, Feb 25, 2021, $15M — Oriental Fortune Capital, YuanBio Venture, E-Town International Industrial Investment, Guangzhou Cherami Sun Tour Equity Investment Management, E-town Sun Fund

## Investors

- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Angel, Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Angel, Series A
- Guangzhou Cherami Sun Tour Equity Investment Management — Angel
- E-town Sun Fund (https://capitalatlas.ai/funds/e-town-sun-fund) — Angel, Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series A
- Zhuhai Hengqin Kangju Private Equity Fund Management Co., Ltd. — Series A